Can I Take Reishi Mushroom with Zetia (Ezetimibe)?

What Ezetimibe Does and Why Reishi Raises Questions

Ezetimibe (brand name Zetia) works at the brush border of the small intestine, blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter that absorbs dietary and biliary cholesterol. The IMPROVE-IT trial (N=18,144) demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite cardiovascular endpoint by 6.4% over seven years compared to simvastatin alone (1). Ezetimibe is absorbed in the intestine and then undergoes extensive glucuronidation to form ezetimibe-glucuronide, its active metabolite, which recirculates via enterohepatic recycling (2).

Why Patients Ask About Reishi

Reishi mushroom (Ganoderma lucidum) has been used in traditional East Asian medicine for over 2,000 years. Modern interest centers on its triterpenes (ganoderic acids) and polysaccharides, which show immunomodulatory and lipid-lowering properties in preclinical models (3). Patients on Zetia often explore reishi because both agents target lipid metabolism, raising the question of combination or conflict.

The Core Concern

The interaction question is not about a single dramatic clash. It is about overlapping metabolic pathways, additive effects on liver enzymes, and reishi's well-documented antiplatelet activity. Each of these deserves separate analysis.

Pharmacokinetic Considerations: How These Two Move Through Your Body

Understanding whether reishi changes how ezetimibe is absorbed, distributed, metabolized, or excreted requires examining each step of the pharmacokinetic chain.

Absorption and the NPC1L1 Transporter

Ezetimibe's absorption site is the jejunal brush border. No published data show that Ganoderma lucidum extracts directly inhibit or induce NPC1L1. Reishi polysaccharides are large molecular weight carbohydrates that are poorly absorbed intact, so a direct competition at the transporter level is unlikely (4). Reishi triterpenes are absorbed in the upper GI tract and could theoretically alter intestinal transit time or bile acid composition, which might modestly affect ezetimibe uptake. This remains speculative. No human pharmacokinetic studies have tested the combination.

Hepatic Metabolism and UGT Enzymes

Ezetimibe is glucuronidated primarily by UGT1A1, UGT1A3, and UGT2B15 in the liver and intestinal wall (2). Ganoderic acids from reishi have demonstrated inhibition of certain CYP450 enzymes (CYP3A4, CYP2D6) in vitro (5). Ezetimibe's CYP450 involvement is minimal, which reduces the risk of a classic CYP-mediated drug interaction. The more relevant question is whether reishi triterpenes affect UGT activity. A 2017 in vitro study found that ganoderic acid A inhibited UGT1A1 with an IC50 of approximately 15 µM (6). If UGT1A1 is inhibited, ezetimibe-glucuronide formation could slow, potentially raising free ezetimibe levels. The clinical significance at typical reishi supplement doses has not been established. This is the pharmacokinetic interaction with the strongest theoretical basis.

Enterohepatic Recycling

Ezetimibe-glucuronide is secreted into bile, deconjugated by intestinal bacteria, and reabsorbed. This recycling loop gives ezetimibe an effective half-life of roughly 22 hours (2). Reishi polysaccharides act as prebiotics and may alter gut microbiome composition (7). Theoretically, shifts in bacterial beta-glucuronidase activity could change how much ezetimibe-glucuronide is deconjugated and recycled. This effect has not been measured for this specific pair, but it supports the general advice to separate dosing times.

Pharmacodynamic Overlap: Additive Effects That Matter

Beyond how the drugs move through your body, there are shared physiological targets that create additive risk.

Antiplatelet and Anticoagulant Effects

Reishi inhibits platelet aggregation through multiple mechanisms. A controlled trial of 37 healthy volunteers showed that Ganoderma lucidum extract (1.5 g daily for 4 weeks) significantly inhibited collagen-induced and ADP-induced platelet aggregation compared to placebo (8). Ezetimibe itself does not carry direct antiplatelet activity. But many patients on ezetimibe also take aspirin or other anticoagulants as part of cardiovascular risk management. Adding reishi to that regimen compounds bleeding risk. If you take ezetimibe with a statin and aspirin, adding reishi creates a three-layer antiplatelet situation that warrants explicit discussion with your prescriber.

Hepatotoxicity Signal

Ezetimibe can cause transaminase elevation, though the incidence is low (approximately 1.3% in the IMPROVE-IT cohort receiving ezetimibe/simvastatin vs. 1.3% with simvastatin alone) (1). Reishi, at higher doses or in concentrated extract forms, has been associated with hepatotoxicity in case reports. A 2019 systematic review identified 5 published cases of Ganoderma-associated liver injury, most involving concentrated extracts taken at doses exceeding manufacturer recommendations (9). The mechanism appears to involve direct hepatocellular toxicity from triterpenes. When both agents pose hepatic risk, even a low-probability event from each side becomes more clinically relevant.

Lipid-Lowering Combination

A randomized pilot study of 26 patients with type 2 diabetes found that Ganoderma lucidum polysaccharides (5.4 g/day for 12 weeks) reduced total cholesterol by approximately 8% compared to baseline, though the study was underpowered for definitive conclusions (10). When combined with ezetimibe's 15 to 20% LDL-C reduction as monotherapy, the additive lipid-lowering effect could be beneficial. But it also means patients and clinicians should track lipid panels to avoid overshooting targets, especially if a statin is also in the mix.

Dose-Separation Strategy and Practical Guidance

The most actionable step you can take is structured dose separation and a monitoring schedule.

The Two-Hour Window

Separate ezetimibe and reishi by at least two hours. Take ezetimibe at your usual time (many patients take it in the evening). Take reishi in the morning or at midday with food. This reduces the chance that reishi triterpenes and ezetimibe compete for UGT enzymes during peak absorption phases. Food slows gastric emptying and may buffer the interaction further.

Recommended Monitoring Protocol

A baseline set of labs before adding reishi to an ezetimibe regimen should include:

• ALT and AST to establish liver enzyme baseline
• Platelet count and PT/INR if on concurrent anticoagulants
• Lipid panel (LDL-C, HDL-C, triglycerides, total cholesterol)

Repeat ALT/AST at 6 weeks, then every 3 to 6 months. If ALT rises above 3 times the upper limit of normal, discontinue reishi and recheck in 4 weeks.

Choosing a Reishi Product

Not all reishi supplements are equivalent. Fruiting body extracts differ substantially from mycelium-on-grain products in triterpene content. A 2017 analysis of 19 commercial reishi products found that 74% of mycelium-based products contained negligible ganoderic acid levels, while fruiting body extracts ranged from 0.8% to 4.2% triterpene content (11). For interaction assessment, the triterpene content matters most because ganoderic acids are the compounds implicated in CYP/UGT inhibition and antiplatelet activity. Ask for a certificate of analysis (COA) showing triterpene percentage. Standard clinical doses in published trials range from 1.5 to 9 g of dried extract daily.

Who Should Avoid This Combination Entirely

Some patients should not combine reishi with ezetimibe without explicit specialist approval.

High-Risk Groups

Patients with pre-existing liver disease (fatty liver, hepatitis, cirrhosis) face compounded hepatotoxic risk. Ezetimibe is not contraindicated in compensated liver disease, but adding a supplement with hepatotoxicity case reports increases the margin of concern (9).

Patients on triple antithrombotic therapy (aspirin + P2Y12 inhibitor + anticoagulant) should avoid reishi entirely. The additive antiplatelet effect creates unacceptable bleeding risk without any controlled data to guide dose adjustment.

Surgical Considerations

The American Society of Anesthesiologists recommends discontinuing herbal supplements at least 2 weeks before elective surgery (12). Reishi's antiplatelet activity makes this especially relevant. If you are taking both ezetimibe and reishi and have a procedure scheduled, stop reishi 14 days prior and inform your surgical team.

What to Do If You Are Already Taking Both

If you have been combining reishi and ezetimibe without problems, that is reassuring but does not eliminate the need for monitoring.

Step-by-Step Assessment

1. Check your reishi product. Identify whether it is a fruiting body extract or mycelium-on-grain. Record the dose and triterpene content from the label or COA.
2. Get baseline labs. Request ALT, AST, lipid panel, and CBC with platelet count from your prescriber.
3. Separate doses. If you have been taking them at the same time, shift reishi to at least 2 hours before or after ezetimibe.
4. Report symptoms. Right upper quadrant pain, dark urine, unusual bruising, prolonged bleeding from cuts, or unexplained fatigue all warrant immediate evaluation.
5. Schedule follow-up labs at 6 weeks.

When to Stop Reishi

Discontinue reishi and contact your prescriber if:

• ALT or AST exceeds 3 times the upper limit of normal
• You develop new bruising or bleeding that was not present before
• You experience jaundice (yellowing of skin or eyes)
• Your LDL-C drops below your target range and your clinician did not plan for the additional reduction

The Evidence Gap and What It Means for You

No randomized controlled trial has directly studied the ezetimibe-reishi combination in humans. The interaction assessment relies on mechanistic reasoning: UGT1A1 inhibition by ganoderic acids in vitro (6), antiplatelet activity in a small human trial (8), and hepatotoxicity case reports (9). The Natural Medicines Comprehensive Database rates Ganoderma lucidum interactions with anticoagulant/antiplatelet drugs as "moderate" based on pharmacodynamic reasoning rather than documented case reports.

What Clinicians Typically Recommend

Dr. Tieraona Low Dog, former member of the White House Commission on Complementary and Alternative Medicine, has stated: "The absence of evidence is not evidence of absence. When a supplement has documented antiplatelet activity and the patient is on cardiovascular medications, the default should be informed co-prescribing with monitoring, not dismissal or alarm."

The Endocrine Society's 2020 clinical practice guidelines on lipid management do not specifically address reishi but recommend that clinicians "inquire about all supplement use at each visit and assess for pharmacokinetic and pharmacodynamic interactions" with lipid-lowering agents (13).

This gap means your prescriber's clinical judgment and your lab results are the best guides. The theoretical risks are manageable with monitoring. They are not grounds to panic, but they are grounds to track.

Ezetimibe and Other Mushroom Supplements: A Brief Comparison

Reishi is not the only medicinal mushroom patients ask about. Lion's mane (Hericium erinaceus) has weaker antiplatelet data and no documented UGT inhibition, making it a lower-interaction-risk option for patients seeking cognitive or neurotropic benefits alongside ezetimibe. Cordyceps (Ophiocordyceps sinensis) shares some antiplatelet properties with reishi but has fewer hepatotoxicity signals. Turkey tail (Trametes versicolor) is primarily studied for immune modulation in oncology settings and has minimal interaction data with lipid-lowering drugs.

If your primary goal with reishi is immune support, and the interaction profile concerns you, turkey tail or astragalus may offer a similar mechanism with less pharmacokinetic overlap. Discuss alternatives with your prescriber before switching.

Patients taking ezetimibe 10 mg daily who add reishi at standard doses (1.5 to 5 g dried fruiting body extract) and follow a 2-hour dose separation window, with baseline and 6-week ALT/AST monitoring, represent the lowest-risk approach supported by current evidence.